论文部分内容阅读
目的探讨组蛋白去甲基化酶JMJD2B在肾透明细胞癌和膀胱尿路上皮癌的表达。方法病理确诊肾透明细胞癌患者30例,膀胱尿路上皮癌患者10例。采用免疫组化法检测JMJD2B在人肾透明细胞癌和膀胱尿路上皮癌及其癌旁组织的表达。结果 JMJD2B主要定位于肾透明细胞癌的细胞核中。其在高分化及中分化的肾透明细胞癌组织中呈现弱阳性表达,其阳性表达细胞数仅占10%;但在低分化肾透明细胞癌组织中却表达较少。膀胱尿路上皮癌及其癌旁组织中均无明显JMJD2B表达。结论 JMJD2B在高分化及中分化的肾癌组织中呈现弱阳性表达,在膀胱尿路上皮癌中未见JMJD2B表达。其在肾癌发生、发展中的意义值得进一步研究。
Objective To investigate the expression of histone demethylase JMJD2B in renal clear cell carcinoma and bladder urothelial carcinoma. Methods Thirty cases of renal clear cell carcinoma and 10 cases of bladder urothelial carcinoma were confirmed by pathology. Immunohistochemistry was used to detect the expression of JMJD2B in human renal clear cell carcinoma and bladder urothelial carcinoma and its adjacent tissues. Results JMJD2B mainly located in the nucleus of renal clear cell carcinoma. Its expression in poorly differentiated and moderately differentiated renal clear cell carcinoma tissue showed a weak positive expression, the positive expression of cells accounted for only 10%; but poorly differentiated renal clear cell carcinoma tissue was less expressed. There was no obvious expression of JMJD2B in bladder urothelial carcinoma and its adjacent tissues. Conclusions JMJD2B shows a weak positive expression in well differentiated and differentiated renal cell carcinoma, and no JMJD2B expression in bladder urothelial carcinoma. Its significance in the occurrence and development of renal cell carcinoma deserves further study.